1 H NMR spectroscopy, shifts are referenced to 7.27 ppm for CDCl 3 , 2.50 ppm for (CD 3 ) 2 SO, or 1.94 ppm for CD 3 CN. For 13 C NMR spectroscopy, shifts are referenced to 77.0 ppm for CDCl 3, 39.50 ppm for (CD 3 ) 2 SO, or 1.32 ppm for CD 3 CN. Abbreviations used in the description of resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), br (broad), m (multiplet). Coupling constants (J) are quoted to the nearest 0.1 Hz. Assignments in 13 C NMR spectroscopy were made using the DEPT sequence with secondary pulses at 90° and 135°. High resolution mass spectra were recorded using electrospray ionization (ESI) techniques at the School of Chemistry, University of Nottingham.
Preparation of 5-Diazobarbituric Acids
General Procedure A
To a mixture of the 1,3-dicarbonyl compound (1.0 equiv) and methanesulfonyl azide 1 (1.0-1.1 equiv) in MeCN at 0 °C was added Et 3 N (2.0 equiv) dropwise. The ice bath was removed and the 
5-Diazo-1-methylbarbituric acid (1b)
. 3 The title compound was prepared according to General Procedure A from 1-methylbarbituric acid 4 (710 mg, 5.00 mmol), methanesulfonyl azide (666 mg, 5.50 mmol), and Et 3 N (1.4 mL, 10 mmol) in MeCN (25 mL), and purified by flash column chromatography (5-30% acetone/PhMe) to
give a white solid (616 mg, 73%). Physical and spectroscopic data were in accordance with the literature. 
5-Diazobarbituric acid (1c).
2 General Procedure A was followed using barbituric acid (1.30 g, 10.0 mmol), methanesulfonyl azide (1.33 g, 11.0 mmol), and Et 3 N (2.8 mL, 20 mmol) in MeCN (100 mL). The crude reaction mixture was passed through a short pad of silica gel, eluting with 7:2:1 EtOAc/IPA/H 2 O, concentrated in vacuo, and recrystallized from IMS to provide the title compound (1.10 g, 71%) as a pale yellow crystalline solid. Physical and spectroscopic data were in accordance with the literature. 2144, 1686, 1670, 1440, 1389, 1368, 1334, 1260, 1241, 1220, 1107, 1068, 877, 750 Despite the marginally superior performance of Rh 2 [(S)-TFPTTL] 4 , the more economical catalyst Rh 2 (esp) 2 was chosen for further reaction development.
Rh(II)-Catalyzed Arylation of 5-Diazobarbituric Acids

General Procedure B
A slurry of 5-diazobarbituric acid 1a (364 mg, 2.00 mmol) and Rh 2 (esp) 2 (1.5 mg, 2.0 µmol) in the appropriate arene (2.00 mL) was stirred at room temperature for 24 h. The excess arene was removed in vacuo and the residue was purified by flash column chromatography to provide the 5-arylbarbituric acid, often as a mixture of regioisomers. Recrystallization from IMS/pet. ether provided a sample of the analytically pure para-isomer (recrystallization conditions were not optimized).
according to General Procedure B using benzene (2.00 mL 
1,3-Dimethyl-5-(4-phenoxyphenyl)barbituric acid (2d). A modification of
General Procedure B (in that the reaction scale was 1.00 mmol, the temperature was 30 °C and the reaction time was 7 h) was followed using 5- 
1,3-Dimethyl-5-(4-(trifluoromethoxy)phenyl)barbituric acid (2e). General
Procedure B was followed using trifluoromethoxybenzene (2.00 mL). ether/acetone/AcOH on AcOH-doped SiO 2 ); IR 1677, 1509, 1443, 1422, 1377, 1256, 1211, 1166, 1106 
5-(4-Fluorophenyl)-1,3-dimethylbarbituric acid (2f)
. General Procedure B was followed using fluorobenzene (2.00 mL 
5-(4-Chlorophenyl)-1,3-dimethylbarbituric acid (2g). General Procedure B
was followed using chlorobenzene (2.00 mL). PhMe/pet. ether/acetone/AcOH on AcOH-doped SiO 2 ); IR 1701 IR , 1664 IR , 1492 IR , 1466 IR , 1440 IR , 1420 IR , 1409 IR , 1384 IR , 13171, 1256 IR , 1130 IR , 1092 IR , 1015 
1,3-Dimethyl-5-(3,4-dimethoxyphenyl)barbituric acid (2l). General
Procedure B was followed using veratrole (2.00 mL). IR 2973 IR , 1701 IR , 1609 IR , 1573 IR , 1532 IR , 1513 IR , 1471 IR , 1291 IR , 1243 IR , 1175 IR , 1027 IR 3210; 3092; 1747 , 1714 , 1682 , 1517 , 1427 , 1357 , 1257 , 1226 , 1182 , 1035 1745, 1714, 1682, 1588, 1509, 1489, 1429, 1358, 1253, 1235, 797, 756, 693 and bromide 6 (91 mg, 51%) as white crystalline solids. Data for 6 were as described previously. 6 Data for 7: R f 0.50 (20% acetone/PhMe); m.p. 224-226 °C decomp (CHCl 3 ); IR 3209, 3113, 1719 IR 3209, 3113, , 1701 IR 3209, 3113, , 1478 IR 3209, 3113, , 1454 IR 3209, 3113, , 1343 IR 3209, 3113, , 1236 IR 3209, 3113, , 1208 IR 3209, 3113, , 1010 ; 1 H NMR (500 MHz, CD 3 CN) δ 5-(4-(4-Bromophenoxy)phenyl)-5-(4-isoproplypiperazin-1-yl)barbituric acid (8). 6 MMP inhibitor 8 was synthesized as described previously. 6 To a solution of bromide 6 (59 mg, 0.13 mmol) in MeOH (1.00 mL) was added N-isopropylpiperazine (40 µL, 0.28 mmol) and the mixture was stirred at room temperature for 15 h. The precipitate was collected by filtration and the filter cake washed with cold MeOH (0.50 mL) to provide the MMP inhibitor 8 (46 mg, 70%) as a white crystalline solid. Physical and spectroscopic data were in accordance with the literature. IR 2947 IR , 2908 IR , 2851 IR , 1692 IR , 1660 IR , 1461 IR , 1442 IR , 1414 IR , 1371 IR , 1321 IR , 1264 IR , 1146 
